Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07740317

Neurocognitive Trajectories After BCMA CAR-T

The purpose of this research study is to evaluate cognitive changes over time in participants with relapsed or refractory multiple myeloma who have received chimeric antigen receptor T-cell therapy (CAR-T).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Atrium Health Levine Cancer

Charlotte, North Carolina, 28204, United States

Location contact

Cindy Varga, MD

PRINCIPAL_INVESTIGATOR

Courtney Schepel

CONTACT

[email protected]

980-292-0817

About this study

This is a prospective, consent-based study that will evaluate the changes in neurocognitive impairment over time in relapsed or refractory multiple myeloma (RRMM) patients receiving standard of care (SOC) commercial B-cell maturation antigen (BCMA) CAR-T therapy. This study will evaluate the feasibility of conducting longitudinal cognitive assessments at baseline (-30 days), 1-, 6-, and 12-months post BCMA CAR-T treatment. Baseline assessments will occur prior to SOC BCMA CAR-T therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ability to understand and willingness to sign an IRB-approved informed consent
  • Ability to retain independent decision-making capacity as per the enrolling investigator
  • Age ≥ 18 years of age at the time of consent
  • Scheduled to receive BCMA CAR-T therapy for RRMM as confirmed by the treating clinician
  • Ability to read and understand the English language
  • ECOG 0-2
  • If actively taking benzodiazepine, must be able to hold for 3 hours prior to study assessments as per treating clinician
  • Reliable access to internet access; a tablet, laptop and/or desktop computer with a camera; or willingness to come into the clinic to conduct study procedures as outlined in the Study Calendar- as per participant self-report
  • Ability to complete required assessments, as determined by the treating clinician

Exclusion criteria

  • Active central nervous system (CNS) disease
  • Known neurodegenerative disease or major neurocognitive disorder
  • Stroke and/or traumatic brain injury (TBI) within 12 months
  • Concurrent investigational neuroactive drugs

Treatment and study plan

Standardized neurocognitive testing

Other

Perform standardized neurocognitive testing at baseline and serially at 1-, 6-, and 12-months post-infusion.

Primary outcomes

  1. Clinically significant cognitive impairment

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    For each timepoint in which the Cognitive Assessment Battery is assessed (baseline, 1-, 6-, and 12 months post-CAR-T), the overall clinically significant impairment will be determined as a binary variable. Clinically significant impairment will be determined if 2 individual cognitive tests (from ICCTF or Digit Span subtest) have a standardized score at least 1.5 standard deviations below the mean or if 1 individual cognitive test has a standardized score at least 2 standard deviations below the mean.

Secondary outcomes

  1. Hopkins Verbal Learning Test - Revised (HVLT-R) total recall score

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    HVLT-R recall score will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The total recall score is the sum of the raw scores from the three learning trials. Raw and standardized T-scores will be captured

  2. Hopkins Verbal Learning Test - Revised (HVLT-R) retention score %

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    HVLT-R retention score % will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The retention score % is the delayed recall score divided by the highest raw score from learning trial #2 or learning trial #3.

  3. Hopkins Verbal Learning Test - Revised (HVLT-R) Recognition Discrimination Index (RDI)

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The HVLT-R RDI will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The RDI is the difference between total number of true positives and total number of false positives from the delayed recognition trial. Raw and standardized T-scores will be captured.

  4. Oral Trail-Making Test Part A (OTMT-A) results, seconds

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The OTMT-A results will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The OTMT-A is a count variable indicating number of seconds to complete OTMT Part A. Raw and standardized scores will be captured.

  5. Oral Trail-Making Test Part B (OTMT-B) results, seconds

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The OTMT-B results will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The OTMT-B is a count variable indicating number of seconds to complete OTMT Part B. Raw and standardized scores will be captured.

  6. Controlled Oral Word Association Test (COWAT) results

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The COWAT results will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The COWAT is a count variable indicating number of words named during the test. Raw and standardized scores will be captured.

  7. Wechsler Adult Intelligence Scale (WAIS)-III Digit Span subtest results

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The WAIS-III Digit Span subtest will be capture at baseline, 1-, 6-, and 12-months post-CAR-T. The WAIS-III Digit Span results are a count variable indicating number of trials completed on Digit Span Forward and Backward combined. Raw and standardized scores will be captured.

  8. Number of participants who completed the study

    Time frame: 12 months post-CAR-T

    A binary variable indicating if the participant successfully completed the study, where study completion is defined as completing baseline and at least one post-treatment Cognitive Assessment Battery

  9. Patient Health Questionnaire-9 (PHQ-9) results

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The PHQ-9 includes 9 items that are used to screen for and monitor the severity of depression. The total score ranges from 0 - 27 with higher scores indicating higher depression severity. The PHQ-9 outcome will be evaluated at baseline, 1-, 6-, and 12-months post-CAR-T as a score and as a categorical variable, with categories defined according to standard documentation. None/minimal (0-4), Mild (5-9), Moderate (10-14), Moderately Severe (15-19), Severe (20-27).

  10. Generalized Anxiety Disorder 7-Item (GAD-7) results

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The GAD-7 includes 7 items that are used to screen for and monitor generalized anxiety disorder. The total score ranges from 0 - 21 with higher scores indicating higher anxiety. The GAD-7 outcome will be evaluated at baseline, 1-, 6-, and 12-months post-CAR-T as a score and also as a categorical variable, with categories defined according to standard documentation. Minimal anxiety (0-4), Mild anxiety (5-9), Moderate anxiety (10-14), Severe anxiety (15-19).

  11. Functional Assessment of Cancer Therapy/Cognition (FACT-Cog) V3 Subscale Scores

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The FACT-Cog V3 includes 37 total items that are used to derive 4 subscales (CogPCI, CogPCA, CogQOL, CogOth). For each of the subscales, higher scores indicate better quality of life. Scoring for each subscale is according to standard documentation (FACT-Cog V3 scoring template 05 July 2023). Subscales will not be summed to derive a total score. The following subscales will be evaluated at baseline, 1-, 6-, and 12-months post-CAR-T. Perceived cognitive impairments score (CogPCI) - includes 18 items, with score ranging from 0-72. Perceived cognitive abilities score (CogPCA) - includes 7 items with score ranging from 0-28. Impact of perceived cognitive impairments on quality-of-life score (CogQOL) - includes 4 items, with score ranging from 0-16. Comments from others on cognition score (CogOth) - includes 4 items, with score ranging from 0-16.

  12. Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Scores

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    The PROMIS Fatigue 7a includes 7 items with 5-level Likert scales (Never, Rarely, Sometimes, Often, Always). The total score ranges from 7 - 35 with higher scores indicating more fatigue is being measured. These raw scores will be converted to T-score metrics (and SE) using the scoring manual. PROMIS Fatigue 7a will be assessed at baseline, 1, 6, and 12 months after CAR T.

  13. Hopkins Verbal Learning Test - Revised (HVLT-R) delayed recall score

    Time frame: Baseline, 1-, 6-, and 12-months post-CAR-T

    HVLT-R delayed recall score will be captured at baseline, 1-, 6-, and 12-months post-CAR-T. The delayed recall score is the number of recalled words during the delayed recall portion of the test. Raw and standardized T-scores will be captured.

Study contacts

Contact information is provided by the study sponsor or research team.

Courtney Schepel

CONTACT

[email protected]

980-292-0817

Sponsors and collaborators

Lead sponsor

Wake Forest University Health Sciences

Other

Collaborators

  • Atrium Health Wake Forest Baptist

Registry information

Official study title

Longitudinal Neurocognitive Trajectories After BCMA CAR-T in Multiple Myeloma

Acronym: CAR-T Cog

Important dates

Study start
2026
Primary completion
2029
Study completion
2029
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.